The phospholipase A2 receptor (PLA2R1) is the major autoantigen in primary membranous
nephropathy. Several PLA2R1 epitopes have been characterized, and a retrospective study …

The phospholipase A2 receptor (PLA2R1) is the major autoantigen in idiopathic
membranous nephropathy. However, the value of anti-PLA2R1 antibody titers in predicting …

Background Antibodies against phospholipase A 2 receptor 1 (PLA 2 R1) are found in 80%
of patients with membranous nephropathy, and previous studies described three …

The discovery of the M-type phospholipase A2 receptor (PLA2R) as a major antigen in
idiopathic membranous nephropathy (iMN) was a breakthrough and established iMN as an …

Introduction Personalized treatment for patients with membranous nephropathy requires
accurate prediction of the disease course at an early stage. In this study, we evaluated the …

Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary
membranous nephropathy (MN), even after other treatments have failed. To assess the …

The phospholipase A 2 receptor (PLA 2 R) is the major target antigen in idiopathic
membranous nephropathy. The technique for measuring antibodies against PLA 2 R and …

Introduction Clinical course of membranous nephropathy (MN) is difficult to predict.
Measurement of circulating anti-PLA2R autoantibodies (PLA2R-Ab) and detection in …

Background Membranous nephropathy (MN) is an autoimmune disease induced by
circulating antibodies against the podocyte protein phospholipase A2 receptor 1 (PLA2R1 …

Background: Anti-phospholipase A2 receptor (PLA2R) antibodies are specific to the
diagnosis of primary membranous nephropathy (pMN). The prevalence of positive …